Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials

Abstract Background Dupilumab, a first-in-class therapy targeting the two key cytokines involved in the persistent underlying inflammatory pathway in atopic dermatitis (AD), is approved for treatment of moderate-to-severe AD in Europe, USA, Japan and several other countries. Objective To assess dupilumab effects on SCORing Atopic Dermatitis (SCORAD) and component scores (objective and subjective SCORAD) over time in adults with moderate-to-severe AD. Methods This post hoc analysis included 2,444 patients in four placebo-controlled, double-blind, randomized, phase 3 trials. SOLO 1 and 2 (NCT02277743; NCT02277769) evaluated 16 weeks of dupilumab monotherapy against placebo. CAFÉ (NCT02755649) and CHRONOS (NCT02260986) evaluated dupilumab with concomitant topical corticosteroids (TCS) against TCS alone for 16 and 52 weeks, respectively. Results 2,444 patients randomized to treatment in SOLO 1 and 2 (N = 1,379), CAFÉ (N = 325) and CHRONOS (N = 740) were analyzed. Dupilumab treatment significantly improved overall SCORAD and individual components as early as Week 1 or 2, with significant and clinically meaningful differences vs. control through end of treatment (p < .0001). These results occurred irrespective of dupilumab regimen, 300 mg subcutaneously weekly or every 2 weeks. Conclusions In four large phase 3 trials in adults with moderate-to-severe AD, dupilumab treatment with or without concomitant TCS resulted in rapid and sustained improvements in all SCORAD outcomes vs. placebo or TCS alone. Video Abstract Read the transcript Watch the video on Vimeo © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group

[1]  A. Armstrong,et al.  Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2 , 2020, The Journal of dermatological treatment.

[2]  M. Ardeleanu,et al.  Laboratory safety of dupilumab in moderate‐to‐severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS) , 2019, The British journal of dermatology.

[3]  Mental health burden and comorbidity in atopic dermatitis in US adults , 2019, Journal of the American Academy of Dermatology.

[4]  John D. Davis,et al.  Conjunctivitis in dupilumab clinical trials , 2019, The British journal of dermatology.

[5]  J. Silverberg,et al.  Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis , 2019, American Journal of Clinical Dermatology.

[6]  M. Ardeleanu,et al.  Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis† , 2019, The British journal of dermatology.

[7]  D. Leung,et al.  Epithelial barrier repair and prevention of allergy , 2019, The Journal of clinical investigation.

[8]  D. Margolis,et al.  Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults , 2019, The British journal of dermatology.

[9]  D. Margolis,et al.  Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult Population. , 2019, The Journal of investigative dermatology.

[10]  L. Misery,et al.  Characteristics of Pruritus in Relation to Self-assessed Severity of Atopic Dermatitis. , 2019, Acta dermato-venereologica.

[11]  J. Silverberg,et al.  A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. , 2019, Journal of the American Academy of Dermatology.

[12]  D. Margolis,et al.  Severity strata for POEM, PO-SCORAD, and DLQI in US adults with atopic dermatitis. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[13]  J. Silverberg,et al.  Assessing the severity of atopic dermatitis in clinical trials and practice. , 2018, Clinics in dermatology.

[14]  S. Feldman,et al.  Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis , 2018, JAMA dermatology.

[15]  D. Margolis,et al.  Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[16]  A. Muraro,et al.  Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[17]  A. Muraro,et al.  Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[18]  M. Cork,et al.  Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ) , 2018, The British journal of dermatology.

[19]  J. Silverberg,et al.  Validation of patient‐reported global severity of atopic dermatitis in adults , 2018, Allergy.

[20]  J. Silverberg,et al.  Relationship between EASI and SCORAD severity assessments for atopic dermatitis. , 2017, Journal of Allergy and Clinical Immunology.

[21]  J. Silverberg,et al.  Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis , 2017, The British journal of dermatology.

[22]  A. Drucker,et al.  Patient Burden of Atopic Dermatitis. , 2017, Dermatologic clinics.

[23]  G. Yancopoulos,et al.  Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial , 2017, The Lancet.

[24]  J. Silverberg,et al.  Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. , 2016, The New England journal of medicine.

[25]  J. Ring,et al.  ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[26]  T. Bieber,et al.  Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults. , 2016, Journal of the American Academy of Dermatology.

[27]  Masutaka Furue,et al.  The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. , 2014, The Journal of allergy and clinical immunology.

[28]  F. Alt,et al.  Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes , 2014, Proceedings of the National Academy of Sciences.

[29]  L. Macdonald,et al.  Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice , 2014, Proceedings of the National Academy of Sciences.

[30]  S. Feldman,et al.  Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. , 2014, Journal of the American Academy of Dermatology.

[31]  J. Ravenscroft,et al.  Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods , 2013, The British journal of dermatology.

[32]  Jochen Schmitt,et al.  Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. , 2013, The Journal of allergy and clinical immunology.

[33]  D. Jayne,et al.  SUMMARY OF PRODUCT CHARACTERISTICS , 2014 .

[34]  M. Suárez-Fariñas,et al.  Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. , 2012, The Journal of allergy and clinical immunology.

[35]  S. Takeuchi,et al.  Visual analogue scale: evaluation of the instrument for the assessment of pruritus. , 2012, Acta dermato-venereologica.

[36]  J. Schmitt,et al.  EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference , 2012, Allergy.

[37]  U. Sivaprasad,et al.  Th2 Cytokines and Atopic Dermatitis. , 2011, Journal of clinical & cellular immunology.

[38]  T Reunala,et al.  Patient‐Oriented SCORAD (PO‐SCORAD): a new self‐assessment scale in atopic dermatitis validated in Europe , 2011, Allergy.

[39]  A. Armstrong,et al.  Health Outcome Measures in Atopic Dermatitis: A Systematic Review of Trends in Disease Severity and Quality-of-Life Instruments 1985–2010 , 2011, PloS one.

[40]  C. Bona,et al.  Regulatory Effect of Extracellular Signal-Regulated Kinases (ERK) on Type I Collagen Synthesis in Human Dermal Fibroblasts Stimulated by IL-4 and IL-13 , 2008, International reviews of immunology.

[41]  A Wolkerstorfer,et al.  Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three‐item severity score , 2007, The British journal of dermatology.

[42]  J. Silverberg,et al.  Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder. , 2017, The Journal of investigative dermatology.

[43]  J. Silverberg,et al.  Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. , 2015, The Journal of investigative dermatology.

[44]  T. Bieber Atopic dermatitis. , 2010, Annals of dermatology.

[45]  J. Ring,et al.  Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. , 1997, Dermatology.

[46]  A. Taïeb,et al.  Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. , 1993, Dermatology.

[47]  Julia Brasch,et al.  Severity Scoring of Atopic Dermatitis: The SCORAD Index , 1993 .